Discovery and characterization of selective CDK9 small molecule inhibitors in preclinical tumor models

被引：0
|
作者：
Heuer, Timothy [1 ]
机构：
[1] Exelixis Inc, San Francisco, CA USA
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3314
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Discovery of selective CDK9 small molecule inhibitors: CDK9 inhibition in tumor cells is associated with inhibition of proliferation and induction of apoptosis
    Heuer, T.
    EJC SUPPLEMENTS, 2008, 6 (12): : 94 - 94
  • [2] Characterization of FASN-selective small-molecule inhibitors in preclinical tumor models
    Heuer, Timothy S.
    Chen, Minchao
    Ventura, Richard
    Waszczuk, Joanna
    Yendluri, Satya
    Lai, Julie
    Tep, Samnang
    Feng, Shirley
    Johnson, Russell
    Zaharia, Cristiana
    Buckley, Douglas
    Kemble, George
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [3] Efficacy of FASN-selective small molecule inhibitors in preclinical tumor models
    Heuer, Timothy S.
    Ventura, Richard
    Waszczuk, Joanna
    Mordec, Kasia
    Lai, Julie
    Johnson, Russell
    Hu, Lilly
    Cai, Haiying
    Wagman, Allan
    Buckley, Douglas
    Parish, Stanley T.
    Bruckheimer, Elizabeth
    Kemble, George
    CANCER RESEARCH, 2014, 74 (19)
  • [4] Synthesis and in Vitro Evaluation of Selective CDK9 Inhibitors
    Shao, H.
    Abbas, A. Y.
    Shi, S.
    Foley, D.
    Huang, S.
    Bradshaw, T. D.
    Pepper, C.
    Endicott, J. A.
    Wang, S.
    Fischer, P. M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 84 - 84
  • [5] YK-2168, a potent and selective small molecule CDK9 inhibitor.
    Ding, Charles Z.
    Liu, Yingchun
    Zhou, Wang
    CANCER RESEARCH, 2022, 82 (12)
  • [6] Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments
    Xiao, Lanshu
    Liu, Yi
    Chen, Hui
    Shen, Lisong
    CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [7] Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development
    Liu, Yingchun
    Xu, Zhaobing
    Hu, Lihong
    Xia, Li
    Li, Qi
    Zhou, Wang
    Chen, Yadong
    Li, Wei
    Jiang, Wen
    Zhu, Xingxun
    Gao, Xiao
    Xia, Yuanfeng
    Zhu, Zhenzhen
    Chen, Shuhui
    Ding, Charles Z.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 112
  • [8] A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models
    Yin, Tinggui
    Lallena, Maria J.
    Kreklau, Emiko L.
    Fales, Kevin R.
    Carballares, Santiago
    Torrres, Raquel
    Wishart, Graham N.
    Ajamie, Rose T.
    Cronier, Damien M.
    Iversen, Phillip W.
    Meier, Timothy I.
    Foreman, Robert T.
    Zeckner, Douglas
    Sissons, Sean E.
    Halstead, Bart W.
    Lin, Aimee B.
    Donoho, Gregory P.
    Qian, Yuewei
    Li, Shuyu
    Wu, Song
    Aggarwal, Amit
    Ye, Xiang S.
    Starling, James J.
    Gaynor, Richard B.
    de Dios, Alfonso
    Du, Jian
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (06) : 1442 - 1456
  • [9] In silico design of small molecule inhibitors of CDK9/cyclin T1 interaction
    Randjelovic, Jelena
    Eric, Slavica
    Savic, Vladimir
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2014, 50 : 100 - 112
  • [10] Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection
    Nemeth, G.
    Varga, Z.
    Greff, Z.
    Bencze, G.
    Sipos, A.
    Szantai-Kis, C.
    Baska, F.
    Gyuris, A.
    Kelemenics, K.
    Szathmary, Z.
    Minarovits, J.
    Keri, G.
    Orfi, L.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (03) : 342 - 358
12345